Talking to Patients on Sunscreen Application and the Effects of Visible Light
March 26th 2025An expert discusses how an important part of personalized photoprotection is providing instructions to patients on how and when to apply and reapply sunscreen. It is advised that sunscreen be applied 20 to 30 minutes before going outdoors. It is critical for patients to reapply sunscreen every 2 hours or 4 times a day, depending on the length of time the patient is outdoors.
Personalized Photoprotection Based on Patient Factors
March 19th 2025An expert discusses how dermatologists guide patients in selecting sunscreens based on skin type (fair skin, skin of color, sensitive skin), coexisting conditions, and environmental exposure (blue light, heavy sun). They recommend sun protection factor (SPF) levels and key ingredients and address adherence barriers. Beyond sunscreen, protective clothing, antioxidants, and physical blockers help shield against visible light and infrared radiation.
Impact of Oxidative Stress on Skin Health and the Utility of Antioxidants
March 19th 2025An expert discusses how oxidative stress accelerates skin aging by damaging cells through free radicals, which form from UV exposure. Antioxidants such as vitamins C and E, niacinamide, and polyphenols counteract this damage. Combining antioxidants with sunscreen enhances protection, reducing free radical formation and optimizing skin health.
Laboratory Monitoring for JAK Inhibitors and Key Takeaways
March 18th 2025An expert discusses a comprehensive review of treatment options for a 32-year-old woman with alopecia areata, covering baricitinib dosing (4 mg initially), monitoring requirements vs ritlecitinib, expected outcomes, and considerations for topical immunotherapy vs JAK inhibitors.
Options for Eyebrow and Eyelash Regrowth in a 32-Year-Old Female With Alopecia Areata
March 18th 2025An expert discusses a 32-year-old woman with alopecia areata affecting eyebrows/eyelashes. Treatment options include topical/intralesional steroids, minoxidil, prostaglandin analogues, JAK inhibitors, and cosmetic approaches.
Sunscreen Ingredients for UV and Visible Light Protection
March 12th 2025An expert discusses how UV radiation causes DNA damage, accelerating skin aging and cancer risk. Visible light and infrared radiation induce oxidative stress and hyperpigmentation, especially in darker skin tones. Conventional sunscreens shield against UV radiation but offer limited visible light and infrared protection. Mineral filters (zinc oxide, titanium dioxide) provide broad coverage, while chemical filters (oxybenzone, avobenzone) absorb UV radiation but lack efficacy against visible and infrared radiation.
The Solar Spectrum and Impact on Skin Health
March 12th 2025An expert discusses how UV radiation makes up about 7% of the sun’s energy and penetrates the skin, causing aging, hyperpigmentation, and inflammation. Visible light and infrared radiation contribute to skin damage, with blue light being more harmful than red light due to its deeper penetration.
Discussing Efficacy and Safety of JAK Inhibitors With Patients and Caregivers
March 11th 2025An expert discusses how alopecia areata significantly affects adolescent mental health. Treatment with ritlecitinib requires proper severity assessment via Severity of Alopecia Tool (SALT) score, clear communication of realistic timelines and goals, careful monitoring, and discussion of potential adverse effects. Long-term adherence is crucial for maintaining results.
Patient Considerations for Selecting Treatment for a 16-Year-Old Male With Severe Alopecia Areata
March 11th 2025An expert discusses how treatment for this adolescent boy with severe alopecia areata must balance efficacy with age-appropriate safety, considering psychological impact, growth/development factors, and family preferences while selecting among topical, intralesional, systemic, or emerging biologic options.
Defining Alopecia Areata Severity and Navigating Treatment Options
March 4th 2025An expert discusses how treatment for alopecia areata begins with topical/intralesional therapies for limited disease and progresses to systemic options for extensive involvement or treatment resistance. Treatment decisions are guided by disease severity, patient age, comorbidities, and treatment goals. FDA-approved systemic agents include ritlecitinib (JAK3/TEC inhibitor) and baricitinib (JAK1/2 inhibitor), which block inflammatory pathways to promote hair regrowth with favorable efficacy, though they require monitoring for potential adverse effects.
Alopecia Areata Clinical Presentation and Challenges in Treatment
March 4th 2025An expert discusses how alopecia areata affects approximately 2% of the population globally, with onset typically in childhood or early adulthood. Patients often present with autoimmune comorbidities (thyroid disorders, vitiligo, atopic dermatitis) and psychological distress. Diagnostic challenges include differentiating from other hair loss conditions and predicting disease course. Treatment difficulties involve unpredictable responses, lack of standardized protocols, and addressing both physical symptoms and psychological impact.